[
1. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GA-2LEN study. Allergy. 2011;66:1216-23. DOI: 10.1111/j.1398-9995.2011.02646.x.
]Open DOISearch in Google Scholar
[
2. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600.
]Open DOISearch in Google Scholar
[
3. Schiller JS, Lucas JW, Peregoy JA. Summary health statistics for u.s. Adults: national health interview survey, 2011. Vital Health Stat 10. 2012;(256):1-218.
]Search in Google Scholar
[
4. Him JH, Cho C, Lee EJ, Suh YS, Choi BI, Kim KS. Prevalence and risk factors of chronic rhinosinusitis in South Korea according to diagnostic criteria. Rhinology. 2016;54(4):239-35. DOI: 10.4193/Rhino15.157.
]Open DOISearch in Google Scholar
[
5. Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD, et al. Allergy. 2015;70(5):533-9. DOI: 10.1111/all.12577.
]Open DOISearch in Google Scholar
[
6. Kim C, Han J, Wu T, Bachert C, Fokkens W, Hellings P, et al. Role of biologics in chronic rhinosinusitis with nasal polyposis: state of the art review. Otolaryngol Head Neck Surg. 2021;164(1):57-66. DOI: 10.1177/0194599820939964.
]Open DOISearch in Google Scholar
[
7. Patel GB, Peters AT. The role of biologics in chronic rhinosinusitis with nasal polyps. Ear Nose Throat J. 2021;100(1):44-7. DOI: 10.1177/0145561320964653.
]Open DOISearch in Google Scholar
[
8. Ren L, Zhang N, Zhang L, Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps – state of art. World Allergy Organ J. 2019;12(8):1000050. DOI: 10.1016/j.waojou.2019.100050.
]Open DOISearch in Google Scholar
[
9. Lange B, Holst R, Thilsing T, Baelum J, Kjeldsen A. Quality of life and associated factors in persons with chronic rhinosinusitis in the general population: a prospective questionnaire and clinical cross-sectional study. Clin Otolaryngol. 2013;38(6):474-80. DOI: 10.1111/coa.12189.
]Open DOISearch in Google Scholar
[
10. Benjamin MR, Stevens WW, Li N, Bose S, Grammar L, Kern RC, et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7(3):1010-16. DOI: 10.1016/j.jaip.2018.10.014.
]Open DOISearch in Google Scholar
[
11. Tsetsos N, Goudakos JK, Daskalakis D, Konstantinidis I, Markou K. Monocloncal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018:56:11-21. DOI: 10.4193/Rhino17.156.
]Open DOISearch in Google Scholar
[
12. Bhattacharyya N, Orlandi RR, Grebner J, Martinson M. Cost burden of chronic rhinosinusitis: a claims-based study. Otolaryngol Head Neck Surg. 2011;144(3):440-5. DOI: 10.1177/0194599810391852.
]Open DOISearch in Google Scholar
[
13. Loftus CA, Soler ZM, Koochakzadeh S, Desiato VM, Yoo F, Nguyen SA, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020;10(2):199-207. DOI: 10.1002/alr.22487.
]Open DOISearch in Google Scholar
[
14. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith T. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-5. DOI: 10.1002/lary.26391.
]Open DOISearch in Google Scholar
[
15. Caminati M, Le Pham D, Bagnasco D, Canonica GW. Type 2 immunity in asthma. World Allergy Organ J. 2018;11(1):13. DOI: 10.1186/s40413-018-0192-5.
]Open DOISearch in Google Scholar
[
16. Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45(2):328-46. DOI: 10.1111/cea.12473.
]Open DOISearch in Google Scholar
[
17. Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J allergy Clin Immunol. 2018;141:1543-51.
]Search in Google Scholar
[
18. Schwarts JS, Tajudeen BA, Cohen NA. Medical management of chronic rhino-sinusitis – a review of traditional and novel medical therapies. Expert Opin Investig Drug. 2017;26:1123-30.
]Search in Google Scholar
[
19. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151-2623-32.
]Search in Google Scholar
[
20. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-45.
]Search in Google Scholar
[
21. Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps [News Release] December 1, 2020; San Francisco, CA. Accessed December 1, 2020. https://www.gene.com/media/press-releases/14887/2020-12-01/genentech-announces-fda-approval-of-xola.
]Search in Google Scholar
[
22. European Medicines Agency. Xolair. Omalizumab. [Internet]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xolair. Accessed July 21, 2022.
]Search in Google Scholar
[
23. Van Zele T, Holappels G, Gevaert P, Bachert C. Differences in initial immuno-profiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28:192-8.
]Search in Google Scholar
[
24. Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J, Fransen L, et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003;58:371-9.
]Search in Google Scholar
[
25. GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps. [Internet]. GlaxoSmithKline; July 29, 2021. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-approval-for-nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps/. Accessed 21 July 2022.
]Search in Google Scholar
[
26. European Medicines Agency. Nucala. Mepolizumab. [Internet]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed 24 July 2022.
]Search in Google Scholar
[
27. Steinke JW, Crouse CD, Bradley D, Hise K, Lynch K, Kountakis SE, et al. Characterization of interleukin-4-stimulated nasal polyp fibroblasts. Am J Respir Cell Mol Biol. 2004;30(2):212-9. DOI: 10.1165/rcmb.2003-0071OC.
]Open DOISearch in Google Scholar
[
28. Pinto JM, Mehta N, DeTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhino-sinusitis. Rhinology. 2010;48:318-324. DOI: 10.4193/Rhino09.144.
]Open DOISearch in Google Scholar
[
29. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-6. DOI: 10.1016/j.jaci.2012.07.047.
]Open DOISearch in Google Scholar
[
30. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA. 2016;315(5):469-79. DOI: 10.1001/jama.2015.19330.
]Open DOISearch in Google Scholar
[
31. Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhino-sinusitis with nasal polyposis. Allergy. 2019;74:743-52. DOI: 10.1111/all.13685.
]Open DOISearch in Google Scholar
[
32. Bachert C, Hellings PW, Mullol J, Nacleiro RM, Chao J, Amin N, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019;7(7):2447-49.e2.
]Search in Google Scholar
[
33. Fujieda S, Matsune S, Takeno S, Asako M, Takeuchi M, Fujita H, et al. The effect of dupilumab on intractable chronic rhinosinusitis with nasal polyps in Japan. Laryngoscope. 2021;131:E1770-77.
]Search in Google Scholar
[
34. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-41. DOI: 10.1016/j.jaci.2006.05.031.
]Open DOISearch in Google Scholar
[
35. Bachert C, Sousa AR, Lund AJ, Scadding GK, Gevaert P, Nasser S, et al. reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol. 2017;140(4):1024-31. DOI: 10.1016/j.jaci.2017.05.044.
]Open DOISearch in Google Scholar
[
36. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAB, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-65. DOI: 10.1016/j.jaci.2011.07.056.
]Open DOISearch in Google Scholar
[
37. Controlled clinical study of dupilumab in patients with nasal polyps (SINUS-52). ClinicalTrials.gov Identifier: NCT02898454. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02898454.
]Search in Google Scholar
[
38. A controlled clinical study of dupilumab in patients with bilateral nasal polyps (SINUS-24). ClinicalTrials.gov Identifier: NCT02912468. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02912468.
]Search in Google Scholar
[
39. A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps (POLYP 1). ClinicalTrials.gov Identifier: NCT03280550. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03280550.
]Search in Google Scholar
[
40. A clinical trial of omalizumab in pariticipants with chronic rhinosinusitis with nasal polyps (POLYP 2). ClinicalTrials.gov Identifier: NCT03280537. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03280537.
]Search in Google Scholar
[
41. Effect of mepolizumab in severe bilateral nasal polyps. ClinicalTrials.gov Identifier: NCT03085797. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03085797.
]Search in Google Scholar
[
42. Efficacy and safety study of benralizumab for patients with severe nasal polyposis (OSTRO). ClinicalTrial.gov Identifier: NCT03401229. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03401229.
]Search in Google Scholar
[
43. Nasal polyps: Inflammatory & molecular phenotyping of responders to benralizumab (NAPPREB). ClinicalTrials.gov Identifier: NCT04185012. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04185012.
]Search in Google Scholar
[
44. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31(4):183-4.
]Search in Google Scholar
[
45. Chuang CC, Guillemin I, Bachert C, Lee SE, Hellings PW, Fokkens WJ, et al. Dupilumab in CRSwNP: responder analysis using clinically meaningful efficacy outcome thresholds. Laryngoscope. 2022;132:259-64. DOI: 10.1002/lary.29911.
]Open DOISearch in Google Scholar
[
46. Bachert C, Zinreich SJ, Hellings PW, Mullol J, Hamilos DL, Gavaert P, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020;58(1):10-7. DOI: 10.4193/Rhin18.282.
]Open DOISearch in Google Scholar
[
47. Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309-17.
]Search in Google Scholar
[
48. Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, et al. Biologics for chronic rhinosinusitis. Cochrane Database of Systematic Reviews. 2021;3.
]Search in Google Scholar
[
49. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94(2 Pt 1):176-8. DOI: 10.1288/00005537-198402000-00004.
]Open DOISearch in Google Scholar
[
50. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-56.e4. DOI: 10.1016/j.jaci.2015.12.1324.
]Open DOISearch in Google Scholar
[
51. Camelo A, Rosignoli G, Ohne Y, Stewart RA, Overed-Sayer C, Sleeman MA, et al. IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells. Blood Adv. 2017;1(10):577-89. DOI: 10.1182/bloodadvances.2016002352.
]Open DOISearch in Google Scholar
[
52. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(2):2312-9. DOI: 10.1111/all.13875.
]Open DOISearch in Google Scholar
[
53. Scangas GA, Wu AW, Ting JY, Metson R, Walgama E, Shrime MG, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope. 2021;131(1):E26-33. DOI: 10.1002/lary.28648.
]Open DOISearch in Google Scholar
[
54. Smith KA, Orlandi RR, Rudmik L. Cost of adult rhinosinusitis: A systematic review. Laryngoscope. 2015;125(7):1547-56. DOI: 10.1002/lary.25180.
]Open DOISearch in Google Scholar
[
55. Andreson WC 3rd, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or nor to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367-72. DOI: 10.1016/j.anai.2019.01.018.
]Open DOISearch in Google Scholar
[
56. Lam K, Kern RC, Luong A. Is there a future for biologics in the management of chronic rhinosinusitis? Int Forum Allergy Rhinol. 2016;6(9):935-42. DOI: 10.1002/alr.21780.
]Open DOISearch in Google Scholar
[
57. Wang WW, Lu DM, Zheng M, Zhang JG, Zhang B. TSLP regulates eotaxin-1 production by nasal epithelial cells from patients with eosinophilic CRSwNP. Rhinology. 2018;56(4):370-7. DOI: 10.4193/Rhin17.045.
]Open DOISearch in Google Scholar
[
58. Kim DK, Jin HR, Eun KM, Mo JH, Cho SH, Oh S, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017;72(7):635-45.
]Search in Google Scholar
[
59. Luo X, Li C, Wang Y, Yang G, Xu Y, Li G, et al. Interleukin-33 promotes Th2/Th17 response in eosinophilic and non-eosinophilic nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2020;82(1):34-9.
]Search in Google Scholar
[
60. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593-600. DOI: 10.1016/j.jaci.2013.04.005.
]Open DOISearch in Google Scholar